Characterization of pristane‐induced arthritis,a murine model of chronic disease: Response to antirheumatic agents,expression of joint cytokines,and immunopathology

Objective

To characterize chronic murine pristane‐induced arthritis (PIA) with regard to the response to antirheumatic agents, expression levels of proinflammatory cytokines, and immunopathologic features.

Methods

Male DBA/1 mice were injected intraperitoneally with pristane oil to induce a chronic polyarthritis, which was monitored by visual scoring. Serum antibody and splenocyte responses to a panel of putative joint‐derived autoantigens were measured. Whole paws were evaluated postmortem for changes in the levels of proinflammatory cytokines tumor necrosis factor α (TNFα), interleukin‐1β (IL‐1β), and IL‐6 by enzyme‐linked immunosorbent assay, and standard histopathology techniques were used to determine joint structural changes. Therapeutic studies were performed for up to 8 weeks of dosing with prednisolone, methotrexate, 3 nonsteroidal antiinflammatory drugs (celecoxib, diclofenac, and indomethacin), a p38 MAPK inhibitor, SB242235, and human soluble TNF receptor (sTNFR; etanercept) and murine sTNFR fusion proteins.

Results

Antibody and cellular responses to the putative joint autoantigens revealed a broad extent of autoimmunity in PIA. TNFα, IL‐1β, and IL‐6 were all persistently up‐regulated in PIA joints. Prednisolone, methotrexate, celecoxib, indomethacin, and SB242235 all significantly reduced the arthritis scores. Etanercept was ineffective in reducing the arthritis scores, whereas murine sTNFR produced a significant, but nonsustained, benefit. Only prednisolone significantly reduced the expression of TNFα, IL‐1β, and IL‐6 in the joints. Prednisolone and methotrexate demonstrated the most effective joint protection.

Conclusion

We have markedly extended the characterization of PIA as a murine model of chronic inflammatory arthritis by demonstrating cellular and humoral autoantigenicity, elevation of clinically precedented joint cytokines, and variation in the response to several antirheumatic therapies. PIA offers significant potential for the long‐term study of immunopathologic mechanisms and novel therapies in rheumatoid arthritis.